biostudies-literatureGhosh SIndian Council of Medical ResearchIndian Council of Medical Research (ICMR)e0402623https://www.ebi.ac.uk/biostudies/studies/S-EPMC11237457biostudies-literatureUnknown12(6)Post-kala-azar dermal leishmaniasis (PKDL) patients are a key source of <i>Leishmania donovani</i> parasites, hindering the goal of eliminating visceral leishmaniasis (VL). Monitoring treatment response and parasite susceptibility is essential due to increasing drug resistance. We assessed the drug susceptibility of PKDL isolates (<i>n</i> = 18) from pre-miltefosine (MIL) era (1997-2004) with isolates (<i>n</i> = 16) from the post-miltefosine era (2010-2019) and post-miltefosine treatment relapse isolates (<i>n</i> = 5) towards miltefosine and amphotericin B (AmB) at promastigote stage and towards sodium antimony gluconate (SAG) at amastigote stage. PKDL isolates were examined for mutation in gene-encoding AQP1 transporter, C26882T mutation on chromosome 24, and miltefosine-transporter (MTMicrobiology spectrumAntimony susceptible <i>Leishmania donovani</i>: evidence from <i>in vitro</i> drug susceptibility of parasites isolated from patients of post-kala-azar dermal leishmaniasis in pre- and post-miltefosine era.PMC112374576/9-7(188)2018-ECDIIKumar DRamesh VGhosh SVerma ASalotra PDeep DKSingh RfalseAntimony susceptible <i>Leishmania donovani</i>: evidence from <i>in vitro</i> drug susceptibility of parasites isolated from patients of post-kala-azar dermal leishmaniasis in pre- and post-miltefosine era.Post-kala-azar dermal leishmaniasis (PKDL) patients are a key source of <i>Leishmania donovani</i> parasites, hindering the goal of eliminating visceral leishmaniasis (VL). Monitoring treatment response and parasite susceptibility is essential due to increasing drug resistance. We assessed the drug susceptibility of PKDL isolates (<i>n</i> = 18) from pre-miltefosine (MIL) era (1997-2004) with isolates (<i>n</i> = 16) from the post-miltefosine era (2010-2019) and post-miltefosine treatment relapse isolates (<i>n</i> = 5) towards miltefosine and amphotericin B (AmB) at promastigote stage and towards sodium antimony gluconate (SAG) at amastigote stage. PKDL isolates were examined for mutation in gene-encoding AQP1 transporter, C26882T mutation on chromosome 24, and miltefosine-transporter (MT2024-01-01T00:00:00Z2024 Jun2025-06-01T02:33:14.555Z2025-06-01T02:33:14.555ZS-EPMC112374573871292610.1128/spectrum.04026-23